Literature DB >> 29243735

Orbital decompression for thyroid eye disease: methods, outcomes, and complications.

J M Jefferis1, R K Jones1, Z I Currie1, J H Tan1, S M Salvi1.   

Abstract

PurposeTo determine the safety and effectiveness of orbital decompression for thyroid eye disease (TED) in our unit. To put this in the context of previously published literature.Patients and methodsA retrospective case review of all patients undergoing orbital decompression for TED under the care of one orbital surgeon (SMS) between January 2009 and December 2015. A systematic literature review of orbital decompression for TED.ResultsWithin the reviewed period, 93 orbits of 55 patients underwent decompression surgery for TED. There were 61 lateral (single) wall decompressions, 17 medial one-and-a-half wall, 11 two-and-a-half wall, 2 balanced two wall, and 2 orbital fat only decompressions. For the lateral (single) wall decompressions, mean reduction in exophthalmometry (95% confidence interval (CI) was 4.2 mm (3.7-4.8), for the medial one-and-a-half walls it was 2.9 mm (2.1-3.7), and for the two-and-a-half walls it was 7.6 mm (5.8-9.4). The most common complications were temporary postoperative numbness (29% of lateral decompressions, 17% of other bony decompressions, OR 0.50, 95% CI 0.12-2.11) and new postoperative diplopia (9% of lateral decompressions, 39% of other bony decompressions, OR 6.8, 95% CI 1. 5-30.9). Systematic literature searching showed reduction in exophthalmometry for lateral wall surgery of 3.6-4.8 mm, with new diplopia 0-38% and postoperative numbness 12-50%. For other bony decompressions, reduction in exophthalmometry was 2.5-8.0 mm with new diplopia 0-45% and postoperative numbness up to 52%.ConclusionDiffering approaches to orbital decompression exist. If the correct type of surgery is chosen, then safe, adequate surgical outcomes can be achieved.

Entities:  

Mesh:

Year:  2017        PMID: 29243735      PMCID: PMC5848288          DOI: 10.1038/eye.2017.260

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  44 in total

1.  Endocrine orbitopathy: 11 years retrospective study and review of 102 patients & 196 orbits.

Authors:  Luigi C Clauser; Manlio Galiè; Riccardo Tieghi; Francesco Carinci
Journal:  J Craniomaxillofac Surg       Date:  2011-10-29       Impact factor: 2.078

2.  Image-guided endoscopic orbital decompression for Graves' orbitopathy.

Authors:  Marika R Dubin; Abtin Tabaee; Jennifer T Scruggs; Michael Kazim; Lanny Garth Close
Journal:  Ann Otol Rhinol Laryngol       Date:  2008-03       Impact factor: 1.547

3.  Correlation of retrobulbar volume change with resected orbital fat volume and proptosis reduction after fatty decompression for Graves ophthalmopathy.

Authors:  Shu-Lang Liao; Shih-Wei Huang
Journal:  Am J Ophthalmol       Date:  2011-01-12       Impact factor: 5.258

4.  Proptosis reduction by clinical vs radiological modalities and medial vs inferomedial approaches: comparison following endoscopic transnasal orbital decompression in patients with dysthyroid orbitopathy.

Authors:  Suman Thapa; Ashok K Gupta; Amod Gupta; Vivek Gupta; Pinaki Dutta; Ramandeep S Virk
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2015-04       Impact factor: 6.223

5.  Fat-removal orbital decompression for disfiguring proptosis associated with Graves' ophthalmopathy: safety, efficacy and predictability of outcomes.

Authors:  Emmy Y Li; Tracy Y Kwok; Andy C Cheng; Alex C Wong; Hunter K Yuen
Journal:  Int Ophthalmol       Date:  2014-04-29       Impact factor: 2.031

6.  Rehabilitative orbital decompression for Graves' orbitopathy: risk factors influencing the new onset of diplopia in primary gaze, outcome, and patients' satisfaction.

Authors:  Roberto Rocchi; Riccardo Lenzi; Michele Marinò; Francesco Latrofa; Marco Nardi; Paolo Piaggi; Barbara Mazzi; Maria Antonietta Altea; Aldo Pinchera; Paolo Vitti; Claudio Marcocci; Stefano Sellari-Franceschini
Journal:  Thyroid       Date:  2012-10-16       Impact factor: 6.568

7.  Transconjunctival fat removal combined with conservative medial wall/floor orbital decompression for Graves orbitopathy.

Authors:  Martin R O'Malley; Dale R Meyer
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2009 May-Jun       Impact factor: 1.746

8.  Simultaneous Versus Staged Balanced Decompression for Thyroid-Related Compressive Optic Neuropathy.

Authors:  Chris Y Wu; Andrew W Stacey; Alon Kahana
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2016 Nov/Dec       Impact factor: 1.746

9.  Transcaruncular medial wall orbital decompression: an effective approach for patients with unilateral graves ophthalmopathy.

Authors:  Robert H Hill; Craig N Czyz; Thomas A Bersani
Journal:  ScientificWorldJournal       Date:  2012-04-30

10.  Results of diplopia and strabismus in patients with severe thyroid ophthalmopathy after orbital decompression.

Authors:  Radmilo Roncevic; Zorica Savkovic; Dusan Roncevic
Journal:  Indian J Ophthalmol       Date:  2014-03       Impact factor: 1.848

View more
  10 in total

1.  Principles of Protection of the Eye and Vision in Orbital Surgery.

Authors:  Jenny C Dohlman; Michael K Yoon
Journal:  J Neurol Surg B Skull Base       Date:  2020-08-07

2.  Endoscopic Endonasal versus Transcranial Optic Canal Decompression: A Morphometric, Cadaveric Study.

Authors:  Jun Kim; Aaron R Plitt; Awais Vance; Scott Connors; James Caruso; Babu Welch; Tomas Garzon-Muvdi
Journal:  J Neurol Surg B Skull Base       Date:  2021-05-29

3.  Management of patients with dysthyroid optic neuropathy treated with intravenous corticosteroids and/or orbital decompression surgery.

Authors:  Sandra Rezar-Dreindl; Andrea Papp; Arnulf Baumann; Thomas Neumayer; Katharina Eibenberger; Eva Stifter; Ursula Schmidt-Erfurth
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-06-22       Impact factor: 3.535

Review 4.  2022 Update on Clinical Management of Graves Disease and Thyroid Eye Disease.

Authors:  Thanh D Hoang; Derek J Stocker; Eva L Chou; Henry B Burch
Journal:  Endocrinol Metab Clin North Am       Date:  2022-05-11       Impact factor: 4.748

5.  BIOINFORMATIC ANALYSIS IDENTIFIES POTENTIALLY KEY DIFFERENTIALLY EXPRESSED GENES AND PATHWAYS IN ORBITAL ADIPOSE TISSUES OF PATIENTS WITH THYROID EYE DISEASE.

Authors:  F F Zhu; L Z Yang
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Jan-Mar       Impact factor: 0.877

6.  Comparison of 2-wall versus 3-wall orbital decompression against dysthyroid optic neuropathy in visual function: A retrospective study in a Chinese population.

Authors:  Sheng-Nan Cheng; Yue-Qi Yu; Ya-Yan You; Jin Chen; Xiao-Huan Pi; Xing-Hua Wang; Fa-Gang Jiang
Journal:  Medicine (Baltimore)       Date:  2021-02-26       Impact factor: 1.817

7.  Compressive optic neuropathy (CON) in Graves' disease caused by hypertrophy of levator and superior rectus muscles: A case report.

Authors:  Takahisa Hirokawa; Masashi Mimura; Masahiro Tonari; Yohei Sato; Yasushi Fujita; Junko Matsuo; Hidehiro Oku; Jun Sugasawa; Tsunehiko Ikeda
Journal:  Medicine (Baltimore)       Date:  2021-04-09       Impact factor: 1.817

8.  Endoscopic Orbital Decompression for Graves' Orbitopathy - A Vietnam Study.

Authors:  Thi My Hanh Pham; Chien Thang Nguyen; Quoc Tung Mai; Thi Huong Giang Bui; Dung Hoa Do; Peter McCluskey; Trong Van Pham
Journal:  Clin Ophthalmol       Date:  2021-04-22

Review 9.  Strategies in Surgical Decompression for Thyroid Eye Disease.

Authors:  Anny M S Cheng; Yi-Hsuan Wei; Shu-Lang Liao
Journal:  Oxid Med Cell Longev       Date:  2020-09-09       Impact factor: 6.543

10.  Teprotumumab for the treatment of chronic thyroid eye disease.

Authors:  Shoaib Ugradar; Julia Kang; Andrea L Kossler; Erin Zimmerman; Jenna Braun; Andrew R Harrison; Swaraj Bose; Kimberly Cockerham; Raymond S Douglas
Journal:  Eye (Lond)       Date:  2021-07-09       Impact factor: 4.456

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.